<DOC>
	<DOC>NCT01053429</DOC>
	<brief_summary>This is a regulatory-required non-interventional pharmacovigilance study exploring the safety profile of ziprasidone HCL monohydrate 20mg, 40mg, 60mg, 80mg in the real world patient population, thus, safety (and/or efficacy) signals will be checked at every visit during the contracted study period until the maximum study end date, per the protocol, of April 2010.</brief_summary>
	<brief_title>A Non-Interventional Post-Marketing Surveillance Study to Evaluate the Safety and Efficacy of Zeldox Capsule</brief_title>
	<detailed_description>All patients diagnosed with schizophrenia or acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features will be included in the study.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Patients diagnosed with schizophrenia Patients who have known hypersensitivity to any ingredient of the product Patients who have had a recent acute myocardial infarction Patients who have uncompensated heart failure Patients who have conditions with a potential to increase QT interval (QTinterval prolongation or history of QT prolongation; congenital long QT syndrome; use with other drugs known to increase the QT interval; arrhythmias treated with class I and III antiarrhythmic drugs)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Regulatory Post-Marketing Surveillance</keyword>
	<keyword>Regulatory Pharmacovigilance</keyword>
	<keyword>ziprasidone</keyword>
</DOC>